New York, US–Nov 20, 2018 Creative Biolabs, an industry leader in antibody production and engineering, recently launched its proprietary antibody humanization service. With the brand-new service coupled with its two preceding humanization services, the company aims to deliver optimal humanized antibody services to its clients around the globe.
Humanization is of critical significance to ameliorate the immunogenicity of monoclonal antibodies derived from xenogeneic sources (typically the rodent species), and to advance their activation of the human immune system. This latest humanization service from Creative Biolabs features the humanized immunoglobulin G (IgG) library screening, retaining or even enhancing the initial affinity of xenogeneic antibodies. Moreover, this service averts the time-consuming conversion of single chain fragment variable (scFv) to IgG and the codon optimization of converted IgG. The two processes, which aim for the antibody expression in mammalian cells, may result in deselection of some humanized scFvs and the antibodies with sequences that prevent protein synthesis and phage display in bacterial cells. The deselection, however, can be circumvented with the help of the newest humanization service.
As for the humanized IgG library screening, a scientist from Creative Biolabs explained, “It involves making a mammalian cell surface display library, thus displaying full-size humanized IgG variants, which will be selected later through the fluorescence activated cell sorting (FACS). Specifically, the administration involves three steps. First, select an acceptor human VH and a receptor VL from a subgroup of human antibodies sharing consensus sequences. Second, conduct the CDR grafting. To maintain or lift the affinity of the humanized antibodies, we need to establish a mammalian cell surface display IgG library to display all possible variants of the humanized IgG. The process entails the utilization of the trimer codon technology. Third, create a humanized IgG library.”
To clarify the third step, this scientist added, “We inserted the cloned cDNA of the heavy-chain variants into a mammalian cell surface display vector, and that of the light chain variants into a separate mammalian expression vector. Thereafter, the cDNA from the heavy-chain library and the light-chain library is then mixed and transfected into 293 cells for surface display of functional whole size humanized IgG variants. Finally, we employ FACS to sort ELISA positive mutant binders with a higher affinity than the parent antibody.”
Prior to the use of the humanized IgG library screening, Creative Biolabs adopted the CDR grafting and SDR Grafting, as well as chain shuffling for antibody humanization. Both of the two approaches rely on bio-panning for phage display of humanized scFv variants and selection of high-affinity humanized binders. Basically, the two are computational and biochemical approaches, whereas the library screening is an in vivo approach to evaluating the immunogenicity of the humanizaed antibody in primates. Due to the close similarity of primates to humans in biological nature, the new service will surely accelerate the application of xenogeneic antibodies to humans.
About Creative Biolabs
Creative Biolabs specializes in antibody humanization and affinity maturation. Established by scientists who are dedicated to conquering cancers, the company is committed to offering first-class custom services about antibody production and engineering. Its services cover production of monoclonal antibodies derived from mice, humans, monkeys, rabbits, chickens, dogs, llamas and camels, etc.
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States